A cell-permeable imidazothiazolyl-chromenone compound that reduces cellular midkine/MDK protein level in H441 lung adenocarcinoma cells in a dose-dependent manner (by >90% in 48h at 25nM) via a yet unidentified mechanism. Shown to inhibit the viability of MDK-positive HEK293, H441, and H520 cells (by ≥60% at 500nM in 48h), but not MDK-negative NHLF or HEK293 (by <15% at 500nM in 48h), via apoptosis induction as a result of PI 3-K/AKT signaling inhibition. Intraperitoneal injection is reported to be efficacious in retarding H441 tumor expansion in mice (9mg/kg; 3X to 5X per wk) in vivo.
Primary Target:Midkine
Molecular Formula:C₂₁H₁₃FN₂O₂S
Solubility:DMSO
Storage and Stability:May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
![Midkine Inhibitor, iMDK (MDK Expression Inhibitor, 3-(2-(4-Fluorobenzyl)imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one, 3-(2-(4-Fluorobenzyl)imidazo[2,1-b][1,3]thiazol-6-yl)-2H-chromen-2-one) 10mg](https://aimg.as-1.co.jp/c/85/2074/45/85133520.jpg)